Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000130179 | SCV000185016 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-11-23 | criteria provided, single submitter | clinical testing | The p.V1753I variant (also known as c.5257G>A), located in coding exon 37 of the NF1 gene, results from a G to A substitution at nucleotide position 5257. The valine at codon 1753 is replaced by isoleucine, an amino acid with highly similar properties. This variant was previously reported in the SNPDatabase as rs148540952. Based on data from the NHLBI Exome Sequencing Project (ESP), the A allele has an overall frequency of approximately 0.01% (1/13006) total alleles studied, having been observed in 0.02% (1/4406) African American alleles. To date, this alteration has been detected with an allele frequency of approximately 0.002% (greater than110000alleles tested) in our clinical cohort.This amino acid position is completely conserved on sequence alignment. In addition, this alteration is predicted to be tolerated by in silico analysis.Since supporting evidence is limited at this time, the clinical significance of p.V1753I remains unclear. |
Labcorp Genetics |
RCV000205990 | SCV000260517 | likely benign | Neurofibromatosis, type 1 | 2025-01-14 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001588983 | SCV001474063 | uncertain significance | not provided | 2020-03-12 | criteria provided, single submitter | clinical testing | The NF1 c.5257G>A; p.Val1753Ile variant (rs148540952), also known as c.5194G>A; p.Val1732Ile for NM_000267, is reported in the ClinVar database (Variation ID: 141594). This variant is found in the African population with an allele frequency of 0.04% (10/24782 alleles) in the Genome Aggregation Database. The valine at codon 1753 is highly conserved, but computational analyses (SIFT: Tolerated, PolyPhen-2: Possibly Damaging) predict conflicting effects of this variant on protein structure/function. Due to limited information, the clinical significance of this variant is uncertain at this time. |
Gene |
RCV001588983 | SCV001816886 | likely benign | not provided | 2020-10-08 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 29360550) |
Sema4, |
RCV000130179 | SCV002527608 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-02-16 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV003162581 | SCV003895303 | benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-01-11 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |